Similar tumor cell killing data to that using lapatinib as shown in Figure 1 were obtained using the second- and third-generation ERBB1/2/4 inhibitors afatinib, neratinib, sapatinib, tagrisso, and poziotinib (Figure 1B, not shown). Here, EGFR is linked to neoplasm.